Q-Med trading update for the third quarter of 2009

Q-Med trading update for the third quarter of 2009

In order to ensure that shareholders have up to date information, Q-Med has
deemed it appropriate to provide an interim trading update for the third quarter
of 2009. However, it should be noted that there remains a high degree of
uncertainty given the current economic environment.

Q-Med's revenues in July and August 2009 have been lower than in the same period
in 2008. If revenue development continues at the same rate for the rest of the
quarter, total revenues for the third quarter of 2009 will be approximately 20%
lower than the same period in 2008. This has contributed to a lower overall
operating profit margin for July and August compared to the same period in 2008.
Assuming that the operating profit margin for July and August is maintained for
the rest of the quarter, the overall operating profit for the third quarter will
be approximately 40 MSEK.

Queries should be addressed to: 
Alexander Kotsinas, Vice President and CFO
Tel: +46 735 00 1111
Karin Falck, Director Corporate Communications
Tel: +46 70 974 9015

Q-Med AB is a medical device company. The company develops, manufactures,
markets, and sells primarily medical implants. The majority of the products are
based on the company's patented technology, NASHA™, for the production of
stabilized non-animal hyaluronic acid. The product portfolio today contains:
Restylane® for filling lines and folds, contouring and creating volume in the
face, Macrolane™ for body contouring, Durolane™ for the treatment of
osteoarthritis of the hip and knee joints, Deflux® for the treatment of
vesicoureteral reflux, VUR, (a malformation of the urinary bladder) in children,
and Solesta™ for the treatment of fecal incontinence. Sales are made through the
company's own subsidiaries or distributors in over 70 countries. Q Med today has
about 650 coworkers, with approximately 400 at the company's head office and
production facility in Uppsala, Sweden. Q-Med AB is listed in the Mid Cap
segment of the NASDAQ OMX Nordic. 


Q-Med AB (publ), Seminariegatan 21, SE-752 28 Uppsala, Sweden. Corporate
identity number 556258-6882.
Tel: +46 18 474 90 00. Fax: +46 18 474 90 01. E-mail: info@q-med.com. Web:
www.q-med.com.